Media
Press Releases
December 18, 2025
Lupin Signs Exclusive Licensing Agreement with Neopharmed for Gastroenterology Brand Plasil® in the Philippines and Brazil
December 12, 2025
Lupin Manufacturing Solutions and PolyPeptide Announce Strategic Alliance to Scale Global Peptide Supply Chain
December 5, 2025
Lupin Receives Tentative Approval from U.S. FDA for Siponimod Tablets
December 4, 2025
Lupin and Valorum Enter into an Exclusive Licensing Agreement for Biosimilar Armlupeg™ (Pegfilgrastim-unne) in the United States
December 1, 2025
Lupin Receives Approval from U.S. FDA for Biosimilar Armlupeg™ (Pegfilgrastim-unne)
November 14, 2025
Lupin Launches Risperidone Long-Acting Injectable with 180-day CGT exclusivity in the U.S., the First Product from its Proprietary Long-Acting Injectable Platform PrecisionSphere™
November 13, 2025
Lupin Establishes a New Global Standard in Sustainable Pharma with an S&P Global ESG Score of 91
November 12, 2025
Lupin Receives EIR from U.S. FDA for its Aurangabad (CSN) Facility
November 8, 2025
Lupin Bioresearch Center Receives Zero Observations from U.S. FDA After Successful Inspection and Assessment
Media
Rajalakshmi Azariah
Vice President & Global Head - Corporate Communications
rajalakshmiazariah@lupin.comElise Titan
Director, U.S. Communications
elisetitan@lupin.comSmart Guide
Close
CloseSearch Product
Global Privacy Control Detected
We have detected your Global Privacy Control (GPC) signal. In accordance with applicable privacy laws, we have automatically honored your preference and disabled all non-essential cookies and tracking.
Only necessary cookies required for the website to function are enabled.
Opt-Out Request Honored
We have respected your privacy preference. Your opt-out request through cookie settings or Global Privacy Control signal has been honored.